John Mulligan
-
Startups
Roche to accumulate Good Therapeutics’ lead drug program for $250M, plus milestone funds
Seattle-based Good Therapeutics designs therapies that can be administered systemically for targeted activation in the body. (Good Therapeutics Graphic) Pharmaceutical…
Read More » -
Startups
Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies
Seattle-based Bonum Therapeutics designs therapies that can be administered systemically for targeted activation in the body. (Good Therapeutics Graphic) Seattle…
Read More »
